Copanlisib dihydrochloride

Copanlisib dihydrochloride is an inhibitor of PI3K used in studies of PI3K-Akt-mTOR Signaling. It is especially relevant in cancer, cell signaling, and metabolism models, where defined compound exposure can be linked to growth-factor signaling, survival control, and nutrient-sensing outputs.

By inhibiting PI3K, Copanlisib dihydrochloride can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and metabolism models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving PI3K
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Copanlisib dihydrochloride is appropriate when a defined chemical perturbant is needed to connect PI3K with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and metabolism models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.